DFP-11207 is under clinical development by Delta-Fly Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect DFP-11207’s likelihood of approval (LoA) and phase transition for Esophageal Cancer took place on 16 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 16 Dec 2022 increased DFP-11207’s LoA and PTSR for Gastric Cancer.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their DFP-11207 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
DFP-11207 is under development for the treatment of solid tumors including esophageal cancer, colorectal cancer, gastric cancer, pancreatic cancer and gallbladder cancer. It is administered orally as a capsule. It is 5-fluorouracil derivative. It targets thymidylate synthase enzyme.
Delta-Fly Pharma overview
Delta-Fly Pharma is a biopharmaceutical and healthcare company. The company discovers and develops anti-cancer agents. It’s product portfolio includes DFP-10917, for the treatment of myelogenous leukemia; DFP-14323, an anticancer drug candidate treating lung cancer; DFP-10825, liposome-conjugated RNAi molecule which targets disseminated ovarian and gastric cancer. Delta-Fly Pharma also develops DFP-11207, cancer cell metabolism regulator that treats stomach cancer; DFP-14927, Polymeric anti-cancer agent for the treatment of solid tumors. The company develops novel products using module technology (Module Drug Discovery). It has its operations in Japan, Canada, and China. Delta-Fly Pharma is headquartered in Tokushima-Shi, Tokushima, Japan.
Quick View DFP-11207 LOA Data
|Highest Development Stage|